FDA panel says boxed warning about suicide risk should stay on Pfizer anti-smoking drug

Federal health advisers say a bold-letter warning about suicide risks with Pfizer's Chantix should remain on the anti-smoking drug until it can reevaluated based on new, rigorous study information.